Lucid Diligence Brief: Bayer to Acquire Perfuse Therapeutics for Up to $2.45B to Add Phase 2 PER-001 for Glaucoma and Diabetic Retinopathy

Professional audiences only. Not investment research or advice. UK readers: for persons under Article 19(5) or Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this communication.

What changed, and when

Bayer AG announced a definitive agreement on 06 May 2026 to acquire Perfuse Therapeutics for up to $2.45 billion (Bayer press release, FirstWord Pharma). The deal includes a $300 million upfront payment with the remainder contingent on development, regulatory, and commercial milestones (Reuters).

60-second thesis frame

This acquisition represents a strategic hedge for Bayer as it faces looming biosimilar competition for its blockbuster ophthalmology franchise, Eylea (aflibercept). By securing PER-001, a Phase 2 small molecule endothelin receptor antagonist (ERA), Bayer pivots toward “vascular-centric” neuroprotection in glaucoma and diabetic retinopathy (DR), moving beyond simple intraocular pressure (IOP) or VEGF management (Perfuse Therapeutics). Confidence is bolstered by PER-001’s intravitreal sustained-release implant, which offers 6 month dosing intervals, directly addressing the “treatment burden” fatigue that hampers existing retinal therapies (FirstWord Pharma). However, the endothelin pathway is historically difficult to target without systemic side effects, and the $2.15 billion back-end heavy deal structure indicates that significant clinical validation remains outstanding.

The seven diligence questions

Clinical

Does the Phase 2 data demonstrate vision improvement independent of IOP lowering in glaucoma, or is the benefit purely additive? (Perfuse Pipeline)
What is the incidence of localized edema or inflammation, a known class-side effect of endothelin antagonists when applied to vascularized tissue?

Payer or Access

Will payers grant premium “neuroprotection” pricing for PER-001 in glaucoma, or will it be bucketed with low-cost generic IOP-lowering drops?
Given the 6 month dosing, how does the “per-injection” cost compare to Eylea HD or biosimilars in the DR market? (Regeneron IR)

Ops or Adoption

Does the 25-gauge applicator require specialized training beyond standard anti-VEGF injection techniques used by retinal specialists? (AllSci)

Competitive

How does PER-001 differentiate from the emerging pipeline of sustained-release VEGF inhibitors and gene therapies aiming for 1 year durability?

Team or Cap table

With lead investors like Access Industries and Catalio Capital Management, what specific exit multiples were achieved on the $300 million upfront versus the total bio-buck potential? (Tracxn)

Red flags

Class toxicity: Systemic ERAs have failed in other indications due to fluid retention; any signal of ocular edema in Phase 2 could halt the program (AllSci).
Endpoint Discrepancy: If vision improvement in DR is not accompanied by a reduction in retinal non-perfusion (RNP) area, the disease-modifying claim is weakened (Perfuse Pipeline).
Market Crowding: Rapid Eylea biosimilar entry could erode the premium ophthalmology market before PER-001 completes Phase 3 (Reuters).

Next catalyst

Antitrust clearance and formal closing of the transaction, expected mid-2026, followed by the presentation of full Phase 2 data at a major ophthalmology congress (e.g., AAO or ASRS).

FAQ

What exactly changed by Bayer’s “Acquire Perfuse Therapeutics” news on 06 May 2026, and why does it matter for the ophthalmology market?

Bayer agreed to buy the biotech for up to $2.45 billion to secure PER-001, an endothelin receptor antagonist in Phase 2 development (Bayer press release). This matters because it gives Bayer a novel, non-VEGF mechanism to treat glaucoma and diabetic retinopathy as its top seller, Eylea, faces patent expirations (FirstWord Pharma).

What is the regulatory path after the Bayer/Perfuse deal, and what are the next formal steps in the US and EU?

The deal must first clear antitrust reviews and receive Perfuse stockholder approval before closing (Reuters). Following the close, Bayer is expected to initiate global Phase 3 trials to support eventual FDA and EMA filings for PER-001 (AllSci).

Which endpoints in the PER-001 program drove the acquisition, and how meaningful was the effect size?

The acquisition was driven by Phase 2 data showing “significant improvements in vision” in both glaucoma and diabetic retinopathy patients (FirstWord Pharma). Unlike standard treatments that only lower eye pressure, PER-001 targets ocular blood flow and neuroprotection (Perfuse Pipeline).

What safety issues matter post–announcement, and do they change real-world use?

Potential for increased intraocular pressure or retinal inflammation remains a key monitorable for any intravitreal implant (Regeneron IR). Because PER-001 uses a 25-gauge applicator, safety in clinical trials will determine if it can be used widely in community clinics or requires surgical settings (AllSci).

How will major US payers treat access after the Bayer acquisition of Perfuse?

Payers are likely to scrutinize PER-001’s 6 month durability versus more frequent, cheaper injections (Regeneron IR). If Bayer can prove “disease modification” rather than just symptom management, it may avoid the heavy step-edits typically applied to mature ophthalmology categories (Bayer press release).

Publisher / Disclosure

Publisher: LucidQuest Ventures Ltd. Produced: 06 May 2026, 12:50 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is,” may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. © 2026 LucidQuest Ventures Ltd.

Entities / Keywords

Bayer AG; Perfuse Therapeutics; PER-001; Glaucoma; Diabetic Retinopathy; Endothelin Receptor Antagonist; ERA; Eylea; Aflibercept; Intravitreal Implant; Neuroprotection; Ocular Blood Flow; FDA; EMA; Access Industries; Catalio Capital Management; Retinal Non-perfusion; Sustained Release; Ophthalmology; M&A.